Patents Assigned to Cothera BioScience, Inc.
  • COMBINATION THERAPY FOR CANCERS WITH BRAF MUTATION
    Publication number: 20240059778
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: July 24, 2023
    Publication date: February 22, 2024
    Applicant: COTHERA BIOSCIENCE, INC.
    Inventors: Yiyou CHEN, Chun JIANG
  • COMBINATION THERAPY FOR CANCERS WITH KRAS MUTATION
    Publication number: 20240058339
    Abstract: It relates to a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor, (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor, and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: October 8, 2020
    Publication date: February 22, 2024
    Applicant: COTHERA BIOSCIENCE, INC.
    Inventors: Yiyou CHEN, Chun JIANG
  • Treatment of cancer with TG02
    Patent number: 11865116
    Abstract: The present disclosure provides therapeutic methods of treating a cancer patient with TG02 and a second therapeutic agent, e.g., TG02 and an immune checkpoint inhibitor, TG02 and a COX-2 inhibitor, or TG02 and an immune checkpoint inhibitor and a COX-2 inhibitor.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: January 9, 2024
    Assignee: COTHERA BIOSCIENCE, INC.
    Inventors: Thomas M. Estok, Eckard Weber, Tracy Lee Lawhon
  • COMBINATION THERAPY FOR CANCERS WITH KRAS MUTATION
    Publication number: 20230310436
    Abstract: Provided is a combination therapy for treating cancer with KRAS mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor, (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor, and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: October 8, 2020
    Publication date: October 5, 2023
    Applicant: COTHERA BIOSCIENCE, INC.
    Inventors: Yiyou CHEN, Chun JIANG
  • Combination therapy for cancers with BRAF mutation
    Patent number: 11753476
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: September 12, 2023
    Assignee: Cothera BioScience, Inc.
    Inventors: Yiyou Chen, Chun Jiang
  • COMBINATION THERAPY FOR CANCERS WITH BRAF MUTATION
    Publication number: 20210179718
    Abstract: The present disclosure provides a combination therapy for treating cancer with BRAF mutations comprising administrating to a subject an effective amount of (a) an epidermal growth factor receptor (EGFR) inhibitor; (b) a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and (c) a cyclin dependent kinase (CDK) 4/6 inhibitor. Also provided are compositions and kits related to the combination therapy.
    Type: Application
    Filed: April 8, 2019
    Publication date: June 17, 2021
    Applicant: Cothera BioScience, Inc.
    Inventors: Yiyou CHEN, Chun JIANG